RxDoctor Payments DataLook up a doctor →

Stephen Smith, MD

Hematology & Oncology · Seattle, WANPI 1497925051

Payments from drug & device makers

$12,647,662in general payments, 2019–2025

Across 475 payments — averaging $26,627 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5.9M
  • Beigene, Ltd.$1.6M
  • Merck$1.4M
  • Genentech, Inc.$909K
  • Incyte Corporation$854K
  • Acerta Pharma LLC$781K
  • plus $1.3M from 13 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,647,662 in reported general payments places this provider in the 95th percentile of 349 hematology & oncology providers in Washington.

See all hematology & oncology providers in Washington

Medicare billing

Part B allowed, 2024
$37,707
Medicare patients
139
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →